August 30, 2012
Kyowa Hakko Kirin Announces Temporary Suspension of Patient Enrollment for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer Patients
Tokyo, Japan, August 30, 2012--- Kyowa Hakko Kirin Co., Ltd.,
("Kyowa Hakko Kirin")
announced the temporary suspension of patient enrollment in
an international phase 3 clinical
(ATTENTION) study evaluating the combination of ARQ 197
(tivantinib) and erlotinib in
patients with advanced or metastatic non-small-cell lung
cancer in Asia (Japan, Korea, and
Taiwan) according to the recommendations by Safety Review
Committee
This study is a randomized, double-blinded trial comparing
ARQ197 and erlotinib to placebo and erlotinib. Patient
enrollment has been suspended based on the higher frequency
of
interstitial lung disease cases in the study as one of
drug-related adverse reactions.
Non-small-cell lung cancer is a disease that new drugs with
remarkable efficacy and safety
are expected and Kyowa Hakko Kirin will make further
investigations to find out a possibility to resume the
study.
Kyowa Hakko Kirin signed a license agreement with ArQule for
the exclusive rights to the development and sales of ARQ 197
in Japan and some parts of Asia (China, Korea, and Taiwan) on
April 27th, 2007.
ATTENTION is an abbreviation of Asian Trial of Tivantinib plus Erlotinib vs. Erlotinib for
NSCLC without EGFR Mutation. Please see below for details.
< http://www.kyowa-kirin.co.jp/english/news/2011/e20110809_01.html>
About ARQ 197 (Tivantinib)ARQ 197 is an orally administered low molecular weight compound discovered by ArQule, which selectively inhibits c-Met (receptor tyrosine kinase). c-Met is a hepatocyte growth factor receptor with a high level of expression and activity in a wide variety of solid cancers. The expression of c-Met is reported as being related to the infiltration and metastasis of cancer and correlated with the malignancy of cancer.
About Erlotinib
Erlotinib is an orally administered molecularly targeted drug
that selectively inhibits tyrosine kinase in epidermal growth
factor receptors. It is indicated for non-small-cell lung
cancer and
marketed under the brand name Tarceva®.
Lung cancer can be categorized into two major categories: small cell lung cancer and non-small-cell lung cancer. Non-small-cell lung cancer can be further categorized into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. This clinical study is conducted with non-small-cell carcinoma, excluding squamous cell carcinoma, as the indication.
About Safety Review CommitteeSafety Review Committee is established to evaluate the safety data of the study. The committee will investigate the safety data independent of the sponsor and give an advice(s) to the sponsor.
About Interstitial lung disease
Interstitial lung disease is a disease which belongs to a
diffuse lung disease and its primary lesions are of a
pathological change in alveolus interstitium (alveolus wall)
or peribronchial interstitium. It causes
It causes inflammation, increase of collagen etc. leading to
thickened wall.
Interstitial pneumonia causes a symptom of breathing
difficulty, fever, and dry cough. When the disease
progresses, lung will become fibrotic, be small and hardened.
If this fibrosis takes place extensively, dyspnea may occur
leading to the death.
ArQule is a biotechn ology company in th e United Stat es eng
a ged in the research and devel opme nt of next-g eneratio n,
small molecule cancer ther ape utics.
URL: http://www.arqule.com/
distributed by |